QUARTERLY REPORT

Q3 2026 — Form 10-Q

Q3 2026PDF · 46 pages432 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended
September 26, 2026 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 	04-2209186
(State or other jurisdiction of incorporation or organization) 	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $1.00 par value 	TMO 	New York Stock Exchange
1.450% Notes due 2027 	TMO 27 	New York Stock Exchange
1.750% Notes due 2027 	TMO 27B 	New York Stock Exchange
Floating Rate Notes due 2027 	TMO 27D 	New York Stock Exchange
0.500% Notes due 2028 	TMO 28A 	New York Stock Exchange
1.375% Notes due 2028 	TMO 28 	New York Stock Exchange
1.950% Notes due 2029 	TMO 29 	New York Stock Exchange
0.875% Notes due 2031 	TMO 31 	New York Stock Exchange
2.375% Notes due 2032 	TMO 32 	New York Stock Exchange
3.650% Notes due 2034 	TMO 34 	New York Stock Exchange
3.628% Notes due 2035 	TMO 35A 	New York Stock Exchange
2.875% Notes due 2037 	TMO 37 	New York Stock Exchange
1.500% Notes due 2039 	TMO 39 	New York Stock Exchange
1.875% Notes due 2049 	TMO 49 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to
submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	☒ Accelerated filer 	☐
Non-accelerated filer 	☐ Smaller reporting company 	☐
Emerging growth company 	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of September 26, 2026, the Registrant had 370,515,868 shares of Common Stock outstanding.

-- 1 of 46 --

THERMO FISHER SCIENTIFIC INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 26, 2026
TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION
Item 1. 	Financial Statements (Unaudited) 	3
Condensed Consolidated Balance Sheets 	3
Condensed Consolidated Statements of Income 	4
Condensed Consolidated Statements of Comprehensive Income 	5
Condensed Consolidated Statements of Cash Flows 	6
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity 	7
Notes to Condensed Consolidated Financial Statements 	9
Note 1. Nature of Operations and Summary of Significant Accounting Policies 	9
Note 2. Supplemental Balance Sheet Information 	10
Note 3. Debt and Other Financing Arrangements 	11
Note 4. Fair Value Measurements 	14
Note 5. Commitments and Contingencies 	16
Note 6. Supplemental Income Statement Information 	17
Note 7. Income Taxes 	20
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity 	21
Note 9. Supplemental Cash Flow Information 	21
Note 10. Derivatives 	22
Note 11. Business Segment Information 	24
Note 12. Acquisitions and Divestitures 	28
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	30
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	40
Item 4. 	Controls and Procedures 	40
PART II - OTHER INFORMATION
Item 1. 	Legal Proceedings 	40
Item 1A. 	Risk Factors 	40
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	40
Item 5. 	Other Information 	41
Item 6. 	Exhibits 	41
2

-- 2 of 46 --

THERMO FISHER SCIENTIFIC INC.
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 26, 	December 31,
(In millions except share and per share amounts) 	2026 	2025
Assets
Current assets:
Cash and cash equivalents 	$ 	5,461 	$ 	9,852
Short-term investments 	600 	253
Accounts receivable, less allowances of $135 and $147 	9,625 	8,900
Inventories 	5,643 	5,425
Contract assets, net 	1,691 	1,666
Other current assets 	2,595 	2,612
Total current assets 	25,615 	28,707
Property, plant and equipment, net 	10,577 	10,565
Acquisition-related intangible assets, net 	18,077 	15,838
Other assets 	5,701 	5,871
Goodwill 	54,263 	49,362
Total assets 	$ 	114,233 	$ 	110,343
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations 	$ 	2,262 	$ 	3,533
Accounts payable 	3,087 	3,622
Accrued payroll and employee benefits 	2,069 	1,995
Contract liabilities 	2,941 	2,710
Other accrued expenses 	3,811 	3,329
Total current liabilities 	14,170 	15,189
Deferred income taxes 	1,473 	1,493
Other long-term liabilities 	4,586 	4,273
Long-term obligations 	39,108 	35,852
Redeemable noncontrolling interest 	128 	122
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued 	— 	—
Common stock, $1 par value, 1,200,000,000 shares authorized; 446,511,736 and 445,160,301 shares
issued 	447 	445
Capital in excess of par value 	19,247 	18,563
Retained earnings 	63,740 	59,156
Treasury stock at cost, 75,995,868 and 68,938,831 shares 	(26,408) 	(22,309)
Accumulated other comprehensive income/(loss) 	(2,264) 	(2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity 	54,761 	53,407
Noncontrolling interests 	6 	7
Total equity 	54,767 	53,415
Total liabilities, redeemable noncontrolling interest and equity 	$ 	114,233 	$ 	110,343
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

-- 3 of 46 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(In millions except per share amounts) 	2026 	2025 	2026 	2025
Revenues
Product revenues 	$ 	6,753 $ 	6,489 $ 	19,852 $ 	18,719
Service revenues 	5,384 	4,633 	15,283 	13,623
Total revenues 	12,137 	11,122 	35,136 	32,341
Costs and operating expenses:
Cost of product revenues 	3,338 	3,319 	10,061 	9,683
Cost of service revenues 	3,668 	3,220 	10,633 	9,431
Selling, general and administrative expenses 	2,321 	2,162 	6,835 	6,380
Research and development expenses 	348 	346 	1,048 	1,041
Restructuring and other costs 	199 	135 	346 	316
Total costs and operating expenses 	9,874 	9,182 	28,923 	26,850
Operating income 	2,263 	1,941 	6,213 	5,491
Interest income 	252 	234 	693 	735
Interest expense 	(417) 	(347) 	(1,172) 	(1,054)
Other income/(expense) 	(10) 	(2) 	13 	(18)
Income before income taxes 	2,088 	1,826 	5,746 	5,155
Benefit from/(provision for) income taxes 	(352) 	(207) 	(590) 	(394)
Equity in earnings/(losses) of unconsolidated entities 	(9) 	2 	(32) 	(9)
Net income 	1,727 	1,621 	5,124 	4,751
Less: net income/(loss) attributable to noncontrolling interests
and redeemable noncontrolling interest 	6 	5 	16 	11
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,721 $ 	1,616 $ 	5,108 $ 	4,740
Earnings per share attributable to Thermo Fisher
Scientific Inc.
Basic 	$ 	4.65 $ 	4.28 $ 	13.77 $ 	12.55
Diluted 	$ 	4.64 $ 	4.27 $ 	13.75 $ 	12.53
Weighted average shares
Basic 	370 	378 	371 	378
Diluted 	371 	378 	372 	378
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

-- 4 of 46 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(In millions) 	2026 	2025 	2026 	2025
Comprehensive income/(loss)
Net income 	$ 	1,727 $ 	1,621 $ 	5,124 $ 	4,751
Other comprehensive income/(loss):
Cumulative translation adjustment:
Cumulative translation adjustment (net of tax
provision (benefit) of $(25), $46, $(39), and
$(369)) 	58 	(17) 	38 	(104)
Reclassification adjustment for losses included in
net income 	137 	6 	137 	6
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in
net income (net of tax (provision) benefit of $0, $0,
$1, and $1) 	1 	1 	2 	2
Pension and other postretirement benefit liability
adjustments:
Pension and other postretirement benefit liability
adjustments arising during the period (net of tax
(provision) benefit of $0, $(1), $(1), and $3) 	— 	3 	2 	(8)
Amortization of net loss included in net periodic
pension cost (net of tax (provision) benefit of $1,
$0, $1 and $2) 	2 	2 	4 	6
Total other comprehensive income/(loss) 	197 	(5) 	183 	(98)
Comprehensive income/(loss) 	1,924 	1,616 	5,307 	4,653
Less: comprehensive income/(loss) attributable to
noncontrolling interests and redeemable noncontrolling
interest 	7 	4 	15 	16
Comprehensive income attributable to Thermo Fisher
Scientific Inc. 	$ 	1,917 $ 	1,612 $ 	5,292 $ 	4,637
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

-- 5 of 46 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine months ended
September 26, 	September 27,
(In millions) 	2026 	2025
Operating activities
Net income 	$ 	5,124 	$ 	4,751
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 	945 	758
Amortization of acquisition-related intangible assets 	1,433 	1,294
Change in deferred income taxes 	(676) 	(728)
Stock-based compensation 	261 	226
Other net non-cash expenses 	360 	315
Changes in assets and liabilities, excluding the effects of acquisitions 	(1,580) 	(2,255)
Net cash provided by operating activities 	5,867 	4,361
Investing activities
Purchases of property, plant and equipment 	(1,263) 	(1,060)
Proceeds from sale of property, plant and equipment 	14 	17
Proceeds from cross-currency interest rate swap interest settlements 	284 	218
Acquisitions, net of cash acquired 	(8,877) 	(4,037)
Proceeds from sale of business, net of cash divested 	1,021 	—
Purchases of investments 	(668) 	(351)
Proceeds from sales and maturities of investments 	253 	254
Net proceeds from terminations of cross-currency interest rate swaps 	388 	—
Other investing activities, net 	(26) 	20
Net cash used in investing activities 	(8,874) 	(4,938)
Financing activities
Net proceeds from issuance of debt 	5,238 	2,840
Repayment of debt 	(2,519) 	(1,625)
Proceeds from issuance of commercial paper 	389 	1,095
Repayments of commercial paper 	(389) 	(597)
Purchases of company common stock 	(4,000) 	(2,963)
Dividends paid 	(511) 	(474)
Other financing activities, net 	251 	(1)
Net cash used in financing activities 	(1,541) 	(1,725)
Exchange rate effect on cash 	164 	273
Increase/(decrease) in cash, cash equivalents and restricted cash 	(4,384) 	(2,029)
Cash, cash equivalents and restricted cash at beginning of period 	9,879 	4,040
Cash, cash equivalents and restricted cash at end of period 	$ 	5,494 	$ 	2,011
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

-- 6 of 46 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo
Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests
Total
Equity	(In millions) 	Shares Amount 	Shares Amount
Three months ended September 26, 2026
Balance at June 27, 2026 $ 	121 	446 $ 446 $ 18,870 $ 62,194 	76 $(26,370) $ 	(2,460) $ 	52,679 $ 	7 $ 52,686
Issuance of shares under
stock plans 	— 	1 	1 	282 	— 	— 	(43) 	— 	240 	— 	240
Stock-based compensation 	— 	— 	— 	95 	— 	— 	— 	— 	95 	— 	95
Dividends declared ($0.47
per share) 	— 	— 	— 	— 	(174) 	— 	— 	— 	(174) 	— 	(174)
Net income/(loss) 	5 	— 	— 	— 	1,721 	— 	— 	— 	1,721 	— 	1,722
Other comprehensive
income/(loss) 	1 	— 	— 	— 	— 	— 	— 	196 	196 	— 	196
Contributions from
(distributions to)
noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock
repurchases 	— 	— 	— 	— 	— 	— 	5 	— 	5 	— 	5
Balance at September 26,
2026 	$ 	128 	447 $ 447 $ 19,247 $ 63,740 	76 $(26,408) $ 	(2,264) $ 	54,761 $ 	6 $ 54,767
Three months ended September 27, 2025
Balance at June 28, 2025 $ 	126 	444 $ 444 $ 18,232 $ 55,901 	67 $(21,269) $ 	(2,797) $ 	50,512 $ 	(35) $ 50,476
Issuance of shares under
stock plans 	— 	— 	— 	28 	— 	— 	(32) 	— 	(5) 	— 	(5)
Stock-based compensation 	— 	— 	— 	70 	— 	— 	— 	— 	70 	— 	70
Purchases of company
common stock 	— 	— 	— 	— 	— 	2 	(1,000) 	— 	(1,000) 	— 	(1,000)
Dividends declared ($0.43
per share) 	— 	— 	— 	— 	(163) 	— 	— 	— 	(163) 	— 	(163)
Net income/(loss) 	5 	— 	— 	— 	1,616 	— 	— 	— 	1,616 	1 	1,616
Other comprehensive
income/(loss) 	(1) 	— 	— 	— 	— 	— 	— 	(4) 	(4) 	— 	(4)
Contributions from
(distributions to)
noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock
repurchases 	— 	— 	— 	— 	— 	— 	(9) 	— 	(9) 	— 	(9)
Disposition 	— 	— 	— 	— 	— 	— 	— 	— 	— 	42 	42
Balance at September 27,
2025 	$ 	129 	445 $ 445 $ 18,330 $ 57,354 	69 $(22,310) $ 	(2,801) $ 	51,018 $ 	7 $ 51,024
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

-- 7 of 46 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Continued)
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo
Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests
Total
Equity	(In millions) 	Shares Amount 	Shares Amount
Nine months ended September 26, 2026
Balance at December 31,
2025 	$ 	122 	445 $ 445 $ 18,563 $ 59,156 	69 $(22,309) $ 	(2,448) $ 	53,407 $ 	7 $ 53,415
Issuance of shares under
stock plans 	— 	1 	1 	424 	— 	— 	(67) 	— 	358 	— 	358
Stock-based compensation 	— 	— 	— 	261 	— 	— 	— 	— 	261 	— 	261
Purchases of company
common stock 	— 	— 	— 	— 	— 	7 	(4,000) 	— 	(4,000) 	— 	(4,000)
Dividends declared ($1.41
per share) 	— 	— 	— 	— 	(524) 	— 	— 	— 	(524) 	— 	(524)
Net income/(loss) 	14 	— 	— 	— 	5,108 	— 	— 	— 	5,108 	1 	5,110
Other comprehensive
income/(loss) 	(1) 	— 	— 	— 	— 	— 	— 	184 	184 	— 	184
Contributions from
(distributions to)
noncontrolling interests 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	(2) 	(2)
Excise tax from stock
repurchases 	— 	— 	— 	— 	— 	— 	(33) 	— 	(33) 	— 	(33)
Balance at September 26,
2026 	$ 	128 	447 $ 447 $ 19,247 $ 63,740 	76 $(26,408) $ 	(2,264) $ 	54,761 $ 	6 $ 54,767
Nine months ended September 27, 2025
Balance at December 31,
2024 	$ 	120 	444 $ 444 $ 17,962 $ 53,102 	63 $(19,226) $ 	(2,697) $ 	49,584 $ 	(33) $ 49,551
Issuance of shares under
stock plans 	— 	1 	1 	142 	— 	— 	(58) 	— 	85 	— 	85
Stock-based compensation 	— 	— 	— 	226 	— 	— 	— 	— 	226 	— 	226
Purchases of company
common stock 	— 	— 	— 	— 	— 	6 	(3,000) 	— 	(3,000) 	— 	(3,000)
Dividends declared ($1.29
per share) 	— 	— 	— 	— 	(488) 	— 	— 	— 	(488) 	— 	(488)
Net income/(loss) 	13 	— 	— 	— 	4,740 	— 	— 	— 	4,740 	(1) 	4,738
Other comprehensive
income/(loss) 	5 	— 	— 	— 	— 	— 	— 	(103) 	(103) 	— 	(103)
Contributions from
(distributions to)
noncontrolling interests 	(8) 	— 	— 	— 	— 	— 	— 	— 	— 	(2) 	(2)
Excise tax from stock
repurchases 	— 	— 	— 	— 	— 	— 	(26) 	— 	(26) 	— 	(26)
Disposition 	— 	— 	— 	— 	— 	— 	— 	— 	— 	42 	42
Balance at September 27,
2025 	$ 	129 	445 $ 445 $ 18,330 $ 57,354 	69 $(22,310) $ 	(2,801) $ 	51,018 $ 	7 $ 51,024
The accompanying notes are an integral part of these condensed consolidated financial statements.
8

-- 8 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them
accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through
diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and
government, industrial and applied, as well as healthcare and diagnostics.
Interim Financial Statements
The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the
opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at
September 26, 2026, the results of operations for the three- and nine-month periods ended September 26, 2026 and September 27, 2025, and
the cash flows for the nine-month periods ended September 26, 2026 and September 27, 2025. Interim results are not necessarily indicative of
results for a full year.
The condensed consolidated balance sheet presented as of December 31, 2025, has been derived from the audited consolidated financial
statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not
contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated
financial statements and notes included in this report should be read in conjunction with the 2025 financial statements and notes included in the
company’s Annual Report on Form 10-K. Certain reclassifications of prior year amounts have been made to conform to the current year
presentation.
Note 1 to the consolidated financial statements for 2025 describes the significant accounting estimates and policies used in preparation of the
consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months
ended September 26, 2026.
Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying
unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain
assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for
a material impact on the company's financial statements or disclosures.
Standard 	Description 	Adoption timing and approach
Impact of adoption
or other significant
matters
Standards recently adopted
ASU No. 2023-09, Income Taxes (Topic
740): Improvements to Income Tax
Disclosures
Among other things, new guidance to disclose additional
information about the tax rate reconciliation and income
taxes paid.
2025 annual report and interim
periods thereafter using a
prospective method.
Increased annual
disclosures in Notes
7 and 9
9

-- 9 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Standard 	Description 	Adoption timing and approach
Impact of adoption
or other significant
matters
Standards not yet adopted
ASU No. 2024-03, Income Statement–
Reporting Comprehensive Income–
Expense Disaggregation Disclosures
(Subtopic 220-40): Disaggregation of
Income Statement Expenses
New guidance to disclose specified information about
certain costs and expenses.
2027 annual report and interim
periods thereafter using a
prospective or retrospective
method.
Will increase
disclosures in Note 6
ASU No. 2025-06, Intangibles–Goodwill
and Other–Internal-Use Software
(Subtopic 350-40): Targeted
Improvements to the Accounting for
Internal-Use Software
Among other things, new guidance to modernize the
accounting for costs to develop software for internal use.
2028 annual report and interim
periods thereafter using a
prospective, retrospective, or
modified transition method; early
adoption is permitted.
Currently evaluating
adoption impact,
timing, and method
ASU No. 2025-10, Government Grants
(Topic 832): Accounting for Government
Grants Received by Business Entities
Among other things, establishes guidance for the
recognition, measurement, and presentation of
government grants.
2029 using a retrospective,
modified retrospective, or modified
prospective approach; early
adoption is permitted.
Currently evaluating
adoption impact,
timing, and method
ASU No. 2026-02, Environmental
Credits and Environmental Credit
Obligations (Topic 818)
Among other things, establishes guidance for the
recognition, measurement, presentation, and disclosure
of environmental credits and environmental credit
obligations.
2027 using a modified
retrospective approach.
Not expected to be
material
Note 2. Supplemental Balance Sheet Information
Inventories
The components of inventories are as follows:
(In millions) 	September 26, 2026 	December 31, 2025
Raw materials 	$ 	2,038 	$ 	1,877
Work in process 	938 	889
Finished goods 	2,667 	2,659
Inventories 	$ 	5,643 	$ 	5,425
Contract-related Balances
Contract asset and liability balances are as follows:
(In millions) 	September 26, 2026 	December 31, 2025
Current contract assets, net 	$ 	1,691 	$ 	1,666
Noncurrent contract assets, net 	— 	1
Current contract liabilities 	2,941 	2,710
Noncurrent contract liabilities 	1,084 	1,183
In the three- and nine-month periods ended September 26, 2026, the company recognized revenues of $0.36 billion and $2.37 billion,
respectively, that were included in the contract liabilities balance at December 31, 2025. In the three- and nine-month periods ended
September 27, 2025, the company recognized revenues of $0.41 billion and $2.50 billion, respectively, that were included in the contract
liabilities balance at December 31, 2024.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of
September 26, 2026, was $29.87 billion. The company will recognize revenues for these performance obligations as they are satisfied,
approximately 52% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to
contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.
10

-- 10 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 3. Debt and Other Financing Arrangements
The company’s debt and other financing arrangements are as follows:
Effective interest rate
at September 26, 	September 26, 	December 31,
(Dollars in millions) 	2026 	2026 	2025
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 	$ 	— 	$ 	587
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 	— 	822
4.953% 3-Year Senior Notes, Due 8/10/2026 	— 	600
0.832% 1.5-Year Senior Notes, Due 9/7/2026 (Swiss franc-denominated) 	— 	517
5.00% 3-Year Senior Notes, Due 12/5/2026 	5.16 % 	1,000 	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 	1.65 % 	570 	587
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 	1.96 % 	683 	705
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 	1.18 % 	184 	184
4.80% 5-Year Senior Notes, Due 11/21/2027 	4.99 % 	600 	600
Floating Rate (EURIBOR + 0.280%) 2-Year Senior Notes, Due 12/1/2027 (euro-
denominated) 	3.09 % 	1,139 	1,175
0.790% 3-Year Senior Notes, Due 1/6/2028 (Swiss franc-denominated) 	1.34 % 	106 	111
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 	0.77 % 	911 	940
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 	1.79 % 	398 	416
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 	0.90 % 	184 	185
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 	1.46 % 	683 	705
1.75% 7-Year Senior Notes, Due 10/15/2028 	1.89 % 	700 	700
5.00% 5-Year Senior Notes, Due 1/31/2029 	5.23 % 	1,000 	1,000
1.125% 4-Year Senior Notes, Due 3/7/2029 (Swiss franc-denominated) 	1.26 % 	380 	397
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 	2.08 % 	797 	822
2.60% 10-Year Senior Notes, Due 10/1/2029 	2.74 % 	900 	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 	1.44 % 	30 	30
1.120% 5-Year Senior Notes, Due 1/6/2030 (Swiss franc-denominated) 	1.25 % 	282 	295
4.977% 7-Year Senior Notes, Due 8/10/2030 	5.12 % 	750 	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 	0.89 % 	1,993 	2,056
4.215% 5-Year Senior Notes, Due 2/12/2031 	4.41 % 	1,000 	—
4.200% 5.5-Year Senior Notes Due 3/1/2031 	4.41 % 	500 	500
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 	1.13 % 	1,025 	1,057
2.00% 10-Year Senior Notes, Due 10/15/2031 	2.23 % 	1,200 	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 	1.92 % 	501 	524
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 	2.55 % 	683 	705
4.473% 7-Year Senior Notes, Due 10/7/2032 	4.62 % 	750 	750
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 	1.60 % 	40 	40
11

-- 11 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Effective interest rate
at September 26, 	September 26, 	December 31,
(Dollars in millions) 	2026 	2026 	2025
4.95% 10-Year Senior Notes, Due 11/21/2032 	5.09 % 	600 	600
1.4175% 8-Year Senior Notes, Due 3/7/2033 (Swiss franc-denominated) 	1.49 % 	423 	442
4.550% 7.3-Year Senior Notes, Due 6/15/2033 	4.73 % 	750 	—
5.086% 10-Year Senior Notes, Due 8/10/2033 	5.20 % 	1,000 	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 	1.21 % 	1,709 	1,762
5.20% 10-Year Senior Notes, Due 1/31/2034 	5.34 % 	500 	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 	3.76 % 	854 	881
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 	1.58 % 	137 	137
4.794% 10-Year Senior Notes, Due 10/7/2035 	4.91 % 	750 	750
3.628% 10-Year Senior Notes, Due 12/1/2035 (euro-denominated) 	3.70 % 	1,253 	1,292
4.902% 10-Year Senior Notes, Due 2/12/2036 	5.02 % 	1,300 	—
1.76% 10-Year Senior Notes, Due 3/3/2036 (Swiss franc-denominated) 	1.81 % 	350 	—
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 	2.10 % 	392 	410
1.520% 12-Year Senior Notes, Due 1/6/2037 (Swiss franc-denominated) 	1.56 % 	375 	392
1.6524% 12-Year Senior Notes, Due 3/6/2037 (Swiss franc-denominated) 	1.71 % 	260 	271
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 	2.94 % 	797 	822
4.894% 12-Year Senior Notes, Due 10/7/2037 	5.00 % 	500 	500
1.90% 12-Year Senior Notes, Due 3/3/2038 (Swiss franc-denominated) 	1.95 % 	303 	—
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 	1.73 % 	1,025 	1,057
2.01% 15-Year Senior Notes, Due 3/3/2041 (Swiss franc-denominated) 	2.05 % 	344 	—
2.80% 20-Year Senior Notes, Due 10/15/2041 	2.90 % 	1,200 	1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 	1.78 % 	1,424 	1,468
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 	2.13 % 	93 	93
5.404% 20-Year Senior Notes, Due 8/10/2043 	5.50 % 	600 	600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 	2.06 % 	184 	185
5.30% 30-Year Senior Notes, Due 2/1/2044 	5.37 % 	400 	400
1.49% 20-Year Senior Notes, Due 1/6/2045 (Swiss franc-denominated) 	1.54 % 	223 	233
1.8975% 20-Year Senior Notes, Due 3/7/2045 (Swiss franc-denominated) 	1.95 % 	163 	170
5.546% 20-Year Senior Notes, Due 2/12/2046 	5.64 % 	750 	—
2.11% 20-Year Senior Notes, Due 3/3/2046 (Swiss franc-denominated) 	2.18 % 	163 	—
4.10% 30-Year Senior Notes, Due 8/15/2047 	4.23 % 	750 	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 	1.98 % 	1,139 	1,175
1.47% 25-Year Senior Notes, Due 1/6/2050 (Swiss franc-denominated) 	1.49 % 	395 	413
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 	2.07 % 	854 	881
12

-- 12 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Effective interest rate
at September 26, 	September 26, 	December 31,
(Dollars in millions) 	2026 	2026 	2025
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 	2.43 % 	212 	212
2.06% 30-Year Senior Notes, Due 3/3/2056 (Swiss franc-denominated) 	2.09 % 	239 	—
Other 	— 	1
Total borrowings at par value 	41,405 	39,459
Unamortized discount 	(85) 	(94)
Unamortized debt issuance costs 	(212) 	(194)
Total borrowings at carrying value 	41,108 	39,172
Finance lease liabilities 	262 	213
Less: Short-term obligations and current maturities 	2,262 	3,533
Long-term obligations 	$ 	39,108 	$ 	35,852
EURIBOR - Euro Interbank Offered Rate
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the
amortization of any debt issuance costs.
See Note 4 for fair value information pertaining to the company’s long-term borrowings.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency
revolving credit. The Facility expires on January 7, 2028. The revolving credit agreement calls for interest at either a Term Secured Overnight
Financing Rate (SOFR), EURIBOR-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the
company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this
type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest
Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under
the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a
minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of September 26, 2026, no borrowings
were outstanding under the Facility.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes).
Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement
basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment.
Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds
sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to
par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.
Senior Notes
Interest is payable annually on the euro and public Swiss franc-denominated fixed rate senior notes, quarterly on the euro-denominated floating
rate senior note, and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes, and
Japanese yen-denominated and Swiss franc-denominated private placement notes may be redeemed at a redemption price of 100% of the
principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of the
Japanese yen-denominated and Swiss franc-denominated private placement notes who have entered into cross-currency swap agreements.
The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior
notes, the most restrictive of which limits the ability of the company
13

-- 13 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to
its senior notes at September 26, 2026.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the
following notes outstanding as of September 26, 2026, included in the table above (collectively, the Euronotes) in registered public offerings: the
Floating Rate Senior Notes due 2027, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 3.628% Senior Notes due
2035, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of
Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other
subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)
(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes
and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of
Thermo Fisher International are consolidated in the financial statements of the company.
Note 4. Fair Value Measurements
Fair Value Measurements
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
September 26,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2026 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	2,510 	$ 	2,510 	$ 	— 	$ 	—
Bank time deposits 	600 	600 	— 	—
Investments 	117 	22 	— 	95
Insurance contracts 	313 	— 	313 	—
Derivative contracts 	231 	— 	231 	—
Contingent consideration 	69 	— 	— 	69
Total assets 	$ 	3,839 	$ 	3,132 	$ 	543 	$ 	164
Liabilities
Derivative contracts 	$ 	590 	$ 	— 	$ 	590 	$ 	—
Contingent consideration 	76 	— 	— 	76
Total liabilities 	$ 	667 	$ 	— 	$ 	590 	$ 	76
14

-- 14 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2025 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	6,907 	$ 	6,907 	$ 	— 	$ 	—
Bank time deposits 	250 	250 	— 	—
Investments 	103 	27 	— 	76
Insurance contracts 	280 	— 	280 	—
Derivative contracts 	685 	— 	685 	—
Contingent consideration 	67 	— 	— 	67
Total assets 	$ 	8,292 	$ 	7,184 	$ 	966 	$ 	143
Liabilities
Derivative contracts 	$ 	506 	$ 	— 	$ 	506 	$ 	—
Contingent consideration 	16 	— 	— 	16
Total liabilities 	$ 	522 	$ 	— 	$ 	506 	$ 	16
In the three- and nine-month periods ended September 26, 2026, the company recorded $(9) million and $14 million, respectively, of net
gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income. In the three- and nine-
month periods ended September 27, 2025, the company recorded $8 million and $6 million of net gains/(losses) on investments, which are
included in other income/(expense) in the accompanying statements of income.
The following table provides a rollforward of investments classified as level 3:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Investments
Beginning balance 	$ 	92 	$ 	59 	$ 	76 	$ 	21
Purchases 	3 	6 	19 	44
Ending balance 	$ 	95 	$ 	65 	$ 	95 	$ 	65
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of a qualifying transaction), of the
contingent consideration asset:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Contingent consideration asset
Beginning balance 	$ 	68 	$ 	— 	$ 	67 	$ 	—
Acquisition 	— 	65 	— 	65
Changes in fair value included in earnings 	1 	— 	2 	—
Ending balance 	$ 	69 	$ 	65 	$ 	69 	$ 	65
15

-- 15 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue
milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent
consideration liabilities.
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Contingent consideration liabilities
Beginning balance 	$ 	178 	$ 	5 	$ 	16 	$ 	13
Acquisitions (including assumed balances) 	10 	3 	165 	3
Payments 	(19) 	— 	(28) 	(6)
Changes in fair value included in earnings 	(92) 	4 	(76) 	3
Currency translation 	— 	— 	(1) 	—
Ending balance 	$ 	76 	$ 	12 	$ 	76 	$ 	12
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
September 26, 2026 	December 31, 2025
(In millions) 	Carrying value 	Fair value 	Carrying value 	Fair value
Senior notes 	$ 	41,108 	$ 	36,943 	$ 	39,171 	$ 	36,606
Other 	— 	— 	1 	1
$ 	41,108 	$ 	36,943 	$ 	39,172 	$ 	36,607
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing
rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes
was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 5. Commitments and Contingencies
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot
predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties
regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative
cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of
installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental
contamination at the company’s domestic and international facilities were not material in any period presented. At September 26, 2026, there
have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2025 financial statements
and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are
adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future
events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation
technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial
position, results of operations and cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and
litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability,
intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the
company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a
meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has
16

-- 16 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
no material accruals for pending litigation or claims for which accrual amounts are not disclosed in these interim financial statements and notes,
nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the
company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of
operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers
compensation and other personal injury matters. At September 26, 2026, there have been no material changes to the accruals for pending
product liability, workers compensation, and other personal injury matters disclosed in the company’s 2025 financial statements and notes
included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance
recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating
losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could
have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the
company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the
solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history
as well as the financial condition and ratings of its insurers on an ongoing basis.
Note 6. Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Revenues
Consumables 	$ 	4,870 	$ 	4,679 	$ 	14,665 	$ 	13,638
Instruments 	1,883 	1,811 	5,188 	5,080
Services 	5,384 	4,633 	15,283 	13,623
Consolidated revenues 	$ 	12,137 	$ 	11,122 	$ 	35,136 	$ 	32,341
Revenues by geographic region based on customer location are as follows:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Revenues
North America 	$ 	6,266 	$ 	5,689 	$ 	18,120 	$ 	16,924
Europe 	3,201 	3,005 	9,469 	8,459
Asia-Pacific 	2,240 	2,013 	6,314 	5,824
Other regions 	430 	415 	1,232 	1,135
Consolidated revenues 	$ 	12,137 	$ 	11,122 	$ 	35,136 	$ 	32,341
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
17

-- 17 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenues by business are as follows:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Revenues
Biosciences 	$ 	1,025 $ 	1,023 $ 	3,065 $ 	3,091
Genetic sciences 	702 	720 	2,060 	2,076
BioProduction 	896 	817 	2,730 	2,234
Other 	96 	28 	315 	27
Life Sciences Solutions 	2,719 	2,588 	8,170 	7,428
Chromatography and mass spectrometry 	859 	841 	2,478 	2,398
Chemical analysis 	316 	320 	919 	898
Electron microscopy 	827 	732 	2,167 	2,043
Analytical Instruments 	2,002 	1,893 	5,564 	5,339
Clinical diagnostics 	269 	283 	830 	822
ImmunoDiagnostics 	232 	230 	710 	681
Microbiology 	70 	162 	396 	473
Transplant diagnostics 	131 	125 	386 	362
Healthcare market channel 	454 	444 	1,326 	1,325
Elimination of intrasegment revenues 	(58) 	(70) 	(204) 	(207)
Specialty Diagnostics 	1,098 	1,174 	3,445 	3,456
Laboratory products 	603 	594 	1,779 	1,776
Research and safety market channel 	2,030 	1,861 	5,893 	5,471
Pharma services 	2,029 	1,722 	5,662 	5,123
Clinical research 	2,445 	2,019 	6,969 	5,914
Elimination of intrasegment revenues and other 	(242) 	(226) 	(710) 	(679)
Laboratory Products and Biopharma Services 	6,863 	5,970 	19,592 	17,605
Elimination of intersegment revenues 	(546) 	(503) 	(1,635) 	(1,487)
Consolidated revenues 	$ 	12,137 $ 	11,122 $ 	35,136 $ 	32,341
Restructuring and Other Costs
In the first nine months of 2026, restructuring and other costs primarily included impairments of long-lived assets, continuing charges for
headcount reductions and facility consolidations in an effort to streamline operations, and, to a lesser extent, net charges for pre-acquisition
litigation and other matters, partially offset by gain on the sale of a business. In 2026, severance actions associated with facility consolidations
and cost reduction measures affected approximately 2% of the company’s workforce.
As of October 30, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment,
that it expects will result in additional charges of approximately $180 million, primarily in 2026, and expects to identify additional actions in future
periods.
18

-- 18 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Restructuring and other costs are as follows:
Three months ended 	Nine months ended
(In millions) 	September 26, 2026 	September 26, 2026
Life Sciences Solutions 	$ 	2 	$ 	25
Analytical Instruments 	1 	22
Specialty Diagnostics 	(60) 	(57)
Laboratory Products and Biopharma Services 	256 	350
Corporate 	1 	7
$ 	199 	$ 	346
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the
accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income are
summarized in the notes to the table.
(In millions) 	Total (a)
Balance at December 31, 2025 	$ 	70
Net restructuring charges incurred in 2026 (b) 	101
Payments 	(90)
Currency translation and other 	(4)
Balance at September 26, 2026 	$ 	75
(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b) Excludes $246 million of net charges, including $244 million for a held-for-sale loss in the Laboratory Products and Biopharma Services segment and $72
million of gain on sale of the microbiology business in the Specialty Diagnostics segment.
The company expects to pay accrued restructuring costs primarily through 2026.
Earnings per Share
The company’s earnings per share are as follows:
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(In millions except per share amounts) 	2026 	2025 	2026 	2025
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,721 $ 	1,616 $ 	5,108 $ 	4,740
Basic weighted average shares 	370 	378 	371 	378
Plus effect of: stock options and restricted stock units 	1 	1 	1 	1
Diluted weighted average shares 	371 	378 	372 	378
Basic earnings per share 	$ 	4.65 $ 	4.28 $ 	13.77 $ 	12.55
Diluted earnings per share 	$ 	4.64 $ 	4.27 $ 	13.75 $ 	12.53
Antidilutive stock options excluded from diluted weighted average
shares 	2 	3 	3 	3
19

-- 19 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 7. Income Taxes
The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal
income tax rate to income before provision for income taxes due to the following:
Nine months ended
(Dollars in millions) 	September 26, 2026 	September 27, 2025
U.S. federal statutory tax rate 	$ 	1,207 	21.0 % $ 	1,082 	21.0 %
State and local income taxes, net of federal income tax effect 	72 	1.3 % 	31 	0.6 %
Foreign tax effects 	(955) 	(16.6)% 	(145) 	(2.8)%
Effect of changes in tax laws or rates enacted in the current period 	— 	0.0 % 	9 	0.2 %
Effect of cross-border tax laws 	592 	10.3 % 	16 	0.3 %
Tax credits 	(140) 	(2.4)% 	(180) 	(3.5)%
Changes in valuation allowances 	— 	0.0 % 	(138) 	(2.7)%
Nontaxable or nondeductible items 	5 	0.1 % 	5 	0.1 %
Changes in unrecognized tax benefits 	38 	0.7 % 	(30) 	(0.6)%
Other adjustments 	(228) 	(4.0)% 	(258) 	(5.0)%
Effective tax rate 	$ 	590 	10.3 % $ 	394 	7.6 %
During the first quarter of 2026, the company recorded a deferred tax benefit of $175 million resulting from the recognition of tax attributes
related to domestication transactions. During the second quarter of 2026, the company recorded a deferred tax benefit of $148 million in
jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. During the third quarter of 2026, the
company recorded a deferred tax benefit of $161 million resulting from the recognition of tax attributes related to a domestication transaction.
The company also recorded a $171 million tax expense related to the tax gain associated with the sale of the microbiology division that was
completed during the quarter.
During the first quarter of 2025, the company recorded a deferred tax benefit of $125 million resulting from the recognition of a tax attribute
related to a domestication transaction. During the second quarter of 2025, the company recorded a deferred tax benefit of $153 million related to
capital losses generated as part of intra-entity transactions and a $93 million benefit in jurisdictions where the deferred tax assets are now
expected to be realized due to forecasted income. During the third quarter of 2025, the company recorded $86 million of tax benefits resulting
from tax return reassessments.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate
differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and
foreign taxes that are different than the U.S. federal statutory rate.
Unrecognized Tax Benefits
As of September 26, 2026, the company had $0.41 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the
effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 	2026
Balance at beginning of year 	$ 	419
Additions due to acquisitions 	8
Additions for tax positions of current year 	10
Additions for tax positions of prior years 	21
Settlements 	(46)
Balance at end of period 	$ 	413
20

-- 20 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income/(Loss)
Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:
(In millions)
Cumulative
translation
adjustment
Unrealized
gains/(losses) on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment 	Total
Three months ended September 26, 2026
Balance at June 27, 2026 	$ 	(2,199) $ 	(21) $ 	(241) $ 	(2,460)
Other comprehensive income/(loss) before reclassifications 	58 	— 	— 	58
Amounts reclassified from accumulated other comprehensive
income/(loss) 	136 	1 	2 	139
Net other comprehensive income/(loss) 	194 	1 	2 	196
Balance at September 26, 2026 	$ 	(2,005) $ 	(21) $ 	(239) $ 	(2,264)
Nine months ended September 26, 2026
Balance at December 31, 2025 	$ 	(2,181) $ 	(23) $ 	(245) $ 	(2,448)
Other comprehensive income/(loss) before reclassifications 	38 	— 	2 	40
Amounts reclassified from accumulated other comprehensive
income/(loss) 	138 	2 	4 	144
Net other comprehensive income/(loss) 	176 	2 	6 	184
Balance at September 26, 2026 	$ 	(2,005) $ 	(21) $ 	(239) $ 	(2,264)
Note 9. Supplemental Cash Flow Information
Supplemental cash flow information is as follows:
Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 	$ 	214 	$ 	163
Fair value of acquisition contingent consideration liabilities 	119 	—
Fair value of acquisition contingent consideration asset 	— 	65
Divestiture-related promissory note receivable 	50 	—
Finance lease ROU assets obtained in exchange for new finance lease liabilities 	54 	—
Declared but unpaid dividends 	177 	164
Issuance of stock upon vesting of restricted stock units 	201 	161
Excise tax from stock repurchases 	33 	26
Unsettled share repurchases 	— 	37
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
(In millions) 	September 26, 2026 	December 31, 2025
Cash and cash equivalents 	$ 	5,461 	$ 	9,852
Restricted cash included in other current assets 	10 	5
Restricted cash included in other assets 	22 	22
Cash, cash equivalents and restricted cash 	$ 	5,494 	$ 	9,879
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming
cash in China awaiting government administrative clearance.
21

-- 21 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 10. Derivatives
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
(In millions) 	September 26, 2026 	December 31, 2025
Notional amount
Cross-currency interest rate swaps designated as net investment hedge - euro 	$ 	— 	$ 	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 	1,100 	4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 	11,800 	5,000
Currency exchange contracts 	1,836 	2,248
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities
within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and
statements of income.
Fair value – assets 	Fair value – liabilities
September 26, 	December 31, 	September 26, 	December 31,
(In millions) 	2026 	2025 	2026 	2025
Derivatives designated as hedging instruments
Cross-currency interest rate swaps 	$ 	229 	$ 	684 	$ 	589 	$ 	504
Derivatives not designated as hedging instruments
Currency exchange contracts 	1 	2 	1 	2
Total derivatives 	$ 	231 	$ 	685 	$ 	590 	$ 	506
The following table provides information on the company’s derivative positions subject to master netting arrangements, presented on a net basis,
had the company elected to offset the asset and liability balances of its positions in the consolidated balance sheets:
Fair value – assets 	Fair value – liabilities
September 26, 	December 31, 	September 26, 	December 31,
(In millions) 	2026 	2025 	2026 	2025
Gross amounts recognized in the consolidated balance sheets 	$ 	231 $ 	685 	$ 	590 $ 	506
Gross amounts subject to offset in master netting arrangements not
offset in the consolidated balance sheets 	(201) 	(319) 	(201) 	(319)
Total derivatives, net 	$ 	30 $ 	366 	$ 	389 $ 	187
The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other current assets,
other assets, other current liabilities, or other long-term liabilities. The fair value of the currency exchange contracts is included in the
accompanying balance sheets under the captions other current assets or other accrued expenses.
22

-- 22 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Gain/(loss) recognized
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(In millions) 	2026 	2025 	2026 	2025
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive
income/(loss) to interest expense 	$ 	(1) $ 	(1) $ 	(3) $ 	(3)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in cumulative translation adjustment within other
comprehensive income/(loss) 	26 	13 	368 	(1,225)
Cross-currency interest rate swaps
Included in cumulative translation adjustment within other
comprehensive income/(loss) 	(53) 	239 	(151) 	(395)
Included in interest expense 	103 	67 	299 	201
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 	(1) 	(1) 	— 	(3)
Included in other income/(expense) 	(7) 	30 	(7) 	43
Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the
corresponding, offsetting losses and gains on the underlying hedged transactions.
See Note 1 to the consolidated financial statements for 2025 included in the company’s Annual Report on Form 10-K for additional information
on the company’s risk management objectives and strategies.
23

-- 23 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 11. Business Segment Information
Business Segment Information
The company’s financial performance is reported in four segments. During 2026, there have been no changes to the company’s basis of
segmentation or in the basis of measurement of segment income. Other segment items included in the below tables consist of stock-based
compensation and other incentive compensation expenses, allocations of corporate expenses and certain overhead expenses, as well as
elimination of intersegment and intrasegment profits. Prior period segment expense amounts have been recast to reflect the method for
allocating expenses to segments in the current period.
Three months ended September 26, 2026
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,279 $ 	1,948 $ 	1,090 $ 	6,820 $ 	12,137
Intersegment revenues 	440 	54 	9 	43 	546
2,719 	2,002 	1,098 	6,863 	12,683
Elimination of intersegment revenues 	(546)
Consolidated revenues 	$ 	12,137
Segment Income
Cost of revenues 	1,013 	953 	587 	5,180
Selling, general, and administrative expenses 	481 	323 	160 	661
Research and development expenses 	133 	138 	46 	20
Other segment items 	70 	51 	(35) 	(65)
Segment income 	1,022 	538 	341 	1,067 	2,968
Unallocated amounts
Cost of revenues adjustments 	(9)
Selling, general and administrative expenses adjustments 	20
Restructuring and other costs 	(199)
Amortization of acquisition-related intangible assets 	(519)
Interest income 	252
Interest expense 	(417)
Other income/(expense) 	(10)
Consolidated income before income taxes 	$ 	2,088
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	98,834 $ 	3,597 $ 	3,259 $ 	1,129 $ 	7,414 $ 	114,233
Purchases of property, plant and equipment 	35 	85 	25 	21 	272 	437
Depreciation of property, plant and equipment 	— 	70 	29 	18 	191 	307
24

-- 24 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Three months ended September 27, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,194 $ 	1,847 $ 	1,154 $ 	5,927 $ 	11,122
Intersegment revenues 	394 	46 	20 	43 	503
2,588 	1,893 	1,174 	5,970 	11,626
Elimination of intersegment revenues 	(503)
Consolidated revenues 	$ 	11,122
Segment Income
Cost of revenues 	961 	974 	682 	4,608
Selling, general, and administrative expenses 	471 	306 	175 	577
Research and development expenses 	134 	144 	42 	14
Other segment items 	54 	41 	(46) 	(97)
Segment income 	968 	429 	321 	868 	2,587
Unallocated amounts
Cost of revenues adjustments 	(10)
Selling, general and administrative expenses adjustments 	(66)
Restructuring and other costs 	(135)
Amortization of acquisition-related intangible assets 	(435)
Interest income 	234
Interest expense 	(347)
Other income/(expense) 	(2)
Consolidated income before income taxes 	$ 	1,826
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	88,209 $ 	3,552 $ 	3,189 $ 	1,307 $ 	6,763 $ 	103,020
Purchases of property, plant and equipment 	23 	32 	18 	34 	297 	404
Depreciation of property, plant and equipment 	— 	62 	26 	23 	115 	227
25

-- 25 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Nine months ended September 26, 2026
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	6,853 $ 	5,414 $ 	3,402 $ 	19,467 $ 	35,136
Intersegment revenues 	1,317 	150 	43 	125 	1,635
8,170 	5,564 	3,445 	19,592 	36,771
Elimination of intersegment revenues 	(1,635)
Consolidated revenues 	$ 	35,136
Segment Income
Cost of revenues 	3,097 	2,754 	1,942 	15,086
Selling, general, and administrative expenses 	1,477 	951 	514 	1,935
Research and development expenses 	404 	416 	135 	62
Other segment items 	175 	127 	(133) 	(273)
Segment income 	3,017 	1,317 	987 	2,781 	8,102
Unallocated amounts
Cost of revenues adjustments 	(51)
Selling, general and administrative expenses adjustments 	(59)
Restructuring and other costs 	(346)
Amortization of acquisition-related intangible assets 	(1,433)
Interest income 	693
Interest expense 	(1,172)
Other income/(expense) 	13
Consolidated income before income taxes 	$ 	5,746
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	98,834 $ 	3,597 $ 	3,259 $ 	1,129 $ 	7,414 $ 	114,233
Purchases of property, plant and equipment 	152 	164 	77 	80 	790 	1,263
Depreciation of property, plant and equipment 	— 	209 	82 	63 	593 	945
26

-- 26 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Nine months ended September 27, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	6,263 $ 	5,193 $ 	3,402 $ 	17,483 $ 	32,341
Intersegment revenues 	1,165 	145 	54 	122 	1,487
7,428 	5,339 	3,456 	17,605 	33,828
Elimination of intersegment revenues 	(1,487)
Consolidated revenues 	$ 	32,341
Segment Income
Cost of revenues 	2,741 	2,711 	2,001 	13,685
Selling, general, and administrative expenses 	1,405 	937 	529 	1,760
Research and development expenses 	408 	426 	134 	41
Other segment items 	152 	112 	(139) 	(306)
Segment income 	2,722 	1,153 	932 	2,425 	7,231
Unallocated amounts
Cost of revenues adjustments 	(31)
Selling, general and administrative expenses adjustments 	(99)
Restructuring and other costs 	(316)
Amortization of acquisition-related intangible assets 	(1,294)
Interest income 	735
Interest expense 	(1,054)
Other income/(expense) 	(18)
Consolidated income before income taxes 	$ 	5,155
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	88,209 $ 	3,552 $ 	3,189 $ 	1,307 $ 	6,763 $ 	103,020
Purchases of property, plant and equipment 	85 	101 	75 	92 	707 	1,060
Depreciation of property, plant and equipment 	— 	177 	76 	68 	439 	758
27

-- 27 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 12. Acquisitions and Divestitures
Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets,
resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be
gained from the assembled workforces. These synergies include: the elimination of redundant facilities, functions and staffing; use of the
company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial
infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in
the accompanying financial statements from their respective dates of acquisition.
2026
On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-
based leading provider of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly
complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate
innovation and drive greater productivity. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions) 	Clario
Purchase price
Cash paid 	$ 	5,811
Debt settled 	3,180
Purchase price payable 	115
Fair value of contingent consideration 	113
Cash acquired 	(117)
$ 	9,102
Net assets acquired
Definite-lived intangible assets
Customer relationships 	$ 	2,510
Product technology 	844
Trade names 	19
Backlog 	423
Goodwill 	5,945
Net other assets/(liabilities) 	380
Contract liabilities 	(375)
Deferred tax assets/(liabilities) 	(645)
$ 	9,102
The preliminary allocation of the purchase price for the acquisition of Clario is based on the estimates of the fair value of the purchase price and
net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, contract liabilities and the
related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.
In 2026, the company also acquired, within the Analytical Instruments segment, two proteomics software companies including one in the U.S.
and one in Germany, further strengthening our mass spectrometry and proteomics software capabilities.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2026 are 20 years for customer relationships, 7 years
for product technology, 3 years for trade names, and 6 years for backlog. The weighted-average amortization period for all definite-lived
intangible assets acquired in 2026 is 15 years.
28

-- 28 of 46 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading
provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial
applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies
that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will
expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this
business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions)
Filtration and
separation business
Purchase price
Cash paid 	$ 	3,939
Fair value of contingent consideration 	(66)
Cash acquired 	(9)
$ 	3,865
Net assets acquired
Property, plant and equipment 	$ 	468
Definite-lived intangible assets
Customer relationships 	1,116
Product technology 	388
Trade names 	51
Goodwill 	2,071
Net other assets/(liabilities) 	148
Deferred tax assets/(liabilities) 	(376)
$ 	3,865
In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging
facility to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years
for product technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired
in 2025 is 18 years.
Divestitures
On August 12, 2026, the company sold its microbiology business to Astorg for approximately $1.07 billion, consisting of cash and a promissory
note. The business was part of the Specialty Diagnostics segment. The sale of this business resulted in a pre-tax gain of $72 million, included in
restructuring and other costs. Revenues in 2026, through the date of sale, and for the full year 2025 were $294 million and $476 million,
respectively, net of retained sales through the company's healthcare market and research and safety market channel.
On September 4, 2026, the company entered into an agreement to sell a pharma services manufacturing facility along with customer contracts
and employees from its Laboratory Products and Biopharma Services segment. The company recognized a held-for-sale loss of $244 million in
the third quarter of 2026.
29

-- 29 of 46 --

THERMO FISHER SCIENTIFIC INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains “forward-looking statements”, within the
meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and uncertainties, and are often identified by words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” or similar expressions or words with similar meanings. Any
statements contained herein that are not statements of historical fact should be considered forward-looking statements.
Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations include, among
others, statements regarding:
• financial expectations, including projections of revenues, expenses, margins, earnings, cash flows, liquidity, capital allocation plans,
and tax matters;
• operational matters, including business strategies, productivity initiatives, restructuring activities, cost-reduction programs, and new
product or service developments;
• market and competitive conditions, including customer demand trends, industry dynamics, pricing, and competitive positioning;
• strategic actions, including planned acquisitions, divestitures, investments, and partnerships;
• legal, regulatory, macroeconomic, geopolitical, public health, supply chain, technology, and cybersecurity developments and
their potential impacts on the company; and
• the timing and outcomes of any of the foregoing.
Each forward-looking statement contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations is
inherently uncertain and involves significant risks, assumptions, and factors that could cause actual results to differ materially from those
expressed or implied. Important risks and uncertainties that could cause such differences are detailed under the caption “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission
(SEC).
Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations speak only as of the
dates on which they are made. While the company may elect to update forward-looking statements in the future, it specifically disclaims any
obligation to do so, in the event of new information, future developments, or otherwise, except as required by law.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP
measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the
section “Non-GAAP Measures” later in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying
unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences
research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the
development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government,
industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 11): Life Sciences
Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
30

-- 30 of 46 --

THERMO FISHER SCIENTIFIC INC.
Consolidated Results
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(Dollars in millions except per share amounts) 	2026 	2025 	Change 	2026 	2025 	Change
Revenues 	$ 	12,137 	$ 	11,122 	9 % $ 	35,136 	$ 	32,341 	9 %
GAAP operating income 	2,263 	1,941 	17 % 	6,213 	5,491 	13 %
GAAP operating income margin 	18.6 % 	17.4 % 	1.2 pt 	17.7 % 	17.0 % 	0.7 pt
Adjusted operating income (non-GAAP measure) 	2,968 	2,587 	15 % 	8,102 	7,231 	12 %
Adjusted operating income margin (non-GAAP
measure) 	24.5 % 	23.3 % 	1.2 pt 	23.1 % 	22.4 % 	0.7 pt
GAAP diluted earnings per share attributable to
Thermo Fisher Scientific Inc. 	4.64 	4.27 	9 % 	13.75 	12.53 	10 %
Adjusted earnings per share (non-GAAP measure) 	6.68 	5.79 	15 % 	18.15 	16.30 	11 %
Organic Revenue Growth
Three months ended 	Nine months ended
September 26, 2026 	September 26, 2026
Revenue growth 	9 % 	9 %
Impact of acquisitions/divestitures 	3 % 	4 %
Impact of currency translation 	0 % 	1 %
Organic revenue growth (non-GAAP measure) 	6 % 	4 %
During the third quarter of 2026, customer activity remained strong across our end markets. Revenue growth was very strong in the pharma and
biotech market, as underlying market conditions continued to strengthen. Revenues in the academic and government market were flat. Revenue
in the industrial and applied market was very strong, driven by customer demand for our innovative high-end instruments. Revenue to customers
in the diagnostics and healthcare market also grew slightly. During the third quarter of 2026, sales increased across all major geographies.
Revenue growth was strong in North America and Europe and very strong in Asia-Pacific, including China. Contributions to organic revenue
during the third quarter of 2026 were led by the Laboratory Products and Biopharma Services segment and the Analytical Instruments segment.
During the first nine months of 2026, revenue growth in the pharma and biotech market was strong, with performance driven by strengthening
underlying market conditions. Revenues in the academic and government market were flat. Revenues to customers in the industrial and applied
market were also strong, driven by customer demand for our innovative high-end instruments. Revenues in the diagnostics and healthcare
market grew slightly. During the first nine months of 2026, sales grew in North America. Revenue growth in Asia-Pacific, including China, and
Europe was strong. Contributions to organic revenue during the first nine months of 2026 were led by the Laboratory Products and Biopharma
Services segment.
The company continues to execute its proven growth strategy which consists of three pillars:
• 	High-impact innovation;
• 	Our trusted partner status with customers; and
• 	Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin increased in the third quarter of 2026 due primarily to very strong
productivity improvements, including tariff refunds realized, offset in part by strategic investments. GAAP operating income margin in the third
quarter of 2026 also benefited from the recognition of net credits for changes in contingent consideration that did not occur in 2025, a gain on the
sale of the microbiology business (Note 12), and lower levels of restructuring and other charges incurred for headcount reductions and
consolidation of facilities when compared to the third quarter of 2025 (Note 6); however, this was largely offset by a held-for-sale loss (Note 12).
31

-- 31 of 46 --

THERMO FISHER SCIENTIFIC INC.
GAAP operating income margin and adjusted operating income margin increased in the first nine months of 2026 due primarily to very strong
productivity improvements, offset in part by unfavorable business mix and strategic investments. GAAP operating income margin also benefitted
from lower levels of restructuring and other charges incurred for headcount reductions and consolidation of facilities (Note 6), largely offset by a
held-for-sale loss (Note 12).
The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including
expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research
and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for
employees. The company’s references throughout this discussion to productivity improvements generally refer to the impact of its Practical
Process Improvement (PPI) Business System to address inflation, drive cost efficiencies, improve profitability and, in 2026, the impact of tariff
refunds realized. The benefits of PPI include optimized price realization, reduced costs resulting from implementing continuous improvement
methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation
of facilities, and low cost region manufacturing.
Notable Recent Acquisitions and Divestiture
On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-
based leading provider of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly
complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate
innovation and drive greater productivity.
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading
provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial
applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies
that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will
expand our reach into industries including battery, semiconductor and medical device manufacturing.
On August 12, 2026, the company sold its microbiology business to Astorg. The business was part of the Specialty Diagnostics segment.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in
Note 11 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2025. Accordingly, the following segment
data are reported on this basis.
Three months ended 	Nine months ended
(Dollars in millions) 	September 26, 2026 	September 27, 2025 	September 26, 2026 	September 27, 2025
Revenues
Life Sciences Solutions 	$ 	2,719 $ 	2,588 $ 	8,170 $ 	7,428
Analytical Instruments 	2,002 	1,893 	5,564 	5,339
Specialty Diagnostics 	1,098 	1,174 	3,445 	3,456
Laboratory Products and Biopharma Services 	6,863 	5,970 	19,592 	17,605
Eliminations 	(546) 	(503) 	(1,635) 	(1,487)
Consolidated revenues 	$ 	12,137 $ 	11,122 $ 	35,136 $ 	32,341
32

-- 32 of 46 --

THERMO FISHER SCIENTIFIC INC.
Life Sciences Solutions
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions) September 26,
2026 September 27,
2025 Total
Change Acquisitions/
Divestitures Currency
Translation
Revenues 	$ 	2,719 	$ 	2,588 	5 % 	4 % 	0 % 	1 %
Segment income 	1,022 	968 	6 %
Segment income margin 	37.6 % 	37.4 % 	0.2 pt
The increase in organic revenues in the third quarter of 2026 was primarily driven by the bioproduction business. On a reported basis, the
bioproduction business grew $79 million, which contributed 3 percentage points of reported growth in the segment, driven by higher demand
from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation business. The increase in
segment income margin resulted primarily from exceptionally strong productivity improvements, offset in part by unfavorable business mix, and
the impact from the acquisition of the filtration and separation business.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions) September 26,
2026 September 27,
2025 Total
Change Acquisitions/
Divestitures Currency
Translation
Revenues 	$ 	8,170 	$ 	7,428 	10 % 	7 % 	1 % 	2 %
Segment income 	3,017 	2,722 	11 %
Segment income margin 	36.9 % 	36.6 % 	0.3 pt
The increase in organic revenues in the first nine months of 2026 was driven by the bioproduction business. On a reported basis, the
bioproduction business grew $496 million, driven by higher demand from pharma and biotech customers, as well as the impact from the 2025
acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from exceptionally strong
productivity improvements, partially offset by the impact from the filtration and separation business acquisition, and unfavorable business mix.
Analytical Instruments
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions) September 26,
2026 September 27,
2025 Total
Change Acquisitions/
Divestitures Currency
Translation
Revenues 	$ 	2,002 	$ 	1,893 	6 % 	0 % 	0 % 	6 %
Segment income 	538 	429 	25 %
Segment income margin 	26.9 % 	22.6 % 	4.3 pt
The increase in organic revenues in the third quarter of 2026 was driven by growth in the electron microscopy and chromatography and mass
spectrometry businesses. On a reported basis, the electron microscopy and chromatography and mass spectrometry businesses increased $94
million and $18 million, respectively, which contributed 5 percentage points and 1 percentage point of reported growth in the segment,
respectively. The increase in segment income margin was driven by very strong productivity improvements, favorable volume leverage and
business mix, offset in part by strategic investments.
33

-- 33 of 46 --

THERMO FISHER SCIENTIFIC INC.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 26,
2026
September 27,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	5,564 	$ 	5,339 	4 % 	0 % 	1 % 	3 %
Segment income 	1,317 	1,153 	14 %
Segment income margin 	23.7 % 	21.6 % 	2.1 pt
The increase in organic revenues in the first nine months of 2026 was primarily due to growth in the electron microscopy and chromatography
and mass spectrometry businesses. On a reported basis, the electron microscopy and chromatography and mass spectrometry businesses grew
$123 million and $81 million, respectively, which contributed 2 percentage points each of reported growth in the segment. The increase in
segment income margin was primarily driven by strong productivity improvements.
Specialty Diagnostics
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 26,
2026
September 27,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	1,098 	$ 	1,174 	(6) % 	(6)% 	0 % 	0 %
Segment income 	341 	321 	6 %
Segment income margin 	31.0 % 	27.4 % 	3.6 pt
Organic revenues were flat in the third quarter of 2026. On a reported basis, segment revenues declined, primarily driven by the impact of the
microbiology business divestiture. The increase in segment income margin was driven by exceptionally strong productivity improvements.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 26,
2026
September 27,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	3,445 	$ 	3,456 	0 % 	(2)% 	1 % 	1 %
Segment income 	987 	932 	6 %
Segment income margin 	28.7 % 	27.0 % 	1.7 pt
Organic revenues in the first nine months of 2026 increased, led by the transplant diagnostics and the immunodiagnostics businesses. On a
reported basis, the impact of the microbiology business divestiture was offset by modest growth across the segment’s other businesses. The
increase in segment income margin was primarily due to strong productivity improvements.
Laboratory Products and Biopharma Services
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions) September 26,
2026 September 27,
2025 Total
Change Acquisitions/
Divestitures Currency
Translation
Revenues 	$ 	6,863 	$ 	5,970 	15 % 	6 % 	0 % 	10 %
Segment income 	1,067 	868 	23 %
Segment income margin 	15.5 % 	14.5 % 	1.0 pt
The increase in organic revenues in the third quarter of 2026 was primarily due to growth in the pharma services business, research and safety
market channel, and the clinical research business. On a reported basis, the clinical research business grew $425 million, which contributed 7
percentage points of reported growth in the segment, primarily driven by the impact of the Clario acquisition. The pharma services business and
research and safety market channel grew $306 million and $169 million, respectively, which contributed 5 percentage points and 3 percentage
points, respectively, of reported growth in the segment. The increase in segment income margin was primarily due to strong productivity
improvements, the impact of the Clario acquisition, partially offset by strategic investments.
34

-- 34 of 46 --

THERMO FISHER SCIENTIFIC INC.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 26,
2026
September 27,
2025
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	19,592 	$ 	17,605 	11 % 	4 % 	1 % 	6 %
Segment income 	2,781 	2,425 	15 %
Segment income margin 	14.2 % 	13.8 % 	0.4 pt
The increase in organic revenues in the first nine months of 2026 was primarily due to growth in the clinical research business, research and
safety market channel, and pharma services business. On a reported basis, the clinical research business grew approximately $1.05 billion,
which contributed 6 percentage points of reported growth in the segment, primarily driven by the impact of the Clario acquisition. The pharma
services business and research and safety market channel grew $539 million and $422 million, respectively, which contributed 3 percentage
points and 2 percentage points, respectively, of reported growth in the segment. The increase in segment income margin was primarily due to
strong productivity improvements, offset in part by strategic investments.
Non-operating Items
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(Dollars and shares in millions) 	2026 	2025 	2026 	2025
Net interest expense 	$ 	165 	$ 	113 	$ 	479 	$ 	319
GAAP other income/(expense) 	(10) 	(2) 	13 	(18)
Adjusted other income/(expense) (non-GAAP measure) 	5 	(7) 	(3) 	(19)
GAAP tax rate 	16.9 % 	11.3 % 	10.3 % 	7.6 %
Adjusted tax rate (non-GAAP measure) 	11.6 % 	11.0 % 	11.3 % 	10.4 %
Weighted average diluted shares 	371 	378 	372 	378
Net interest expense (interest expense less interest income) in the third quarter and first nine months of 2026 increased, due primarily to the
increase in debt for general corporate purposes and the company’s capital deployment initiatives, which included financing stock buybacks,
paying dividends, and acquiring Clario (Note 12). In the third quarter and first nine months of 2026, the company’s net interest expense was
reduced by $102 million and $296 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements.
In the third quarter and first nine months of 2025, the company’s net interest expense was reduced by $66 million and $199 million, respectively,
as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 10).
GAAP other income/(expense) and adjusted other income/(expense) include currency transaction gains/losses on non-operating monetary
assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in the
third quarter and first nine months of 2026 also includes $(13) million and $10 million, respectively, of net gains/(losses) on investments. GAAP
other income/(expense) in the first nine months of 2026 also includes $6 million of business interruption recoveries. GAAP other
income/(expense) in the third quarter and first nine months of 2025 also includes $7 million and $9 million, respectively, of net gains on
investments, and $2 million and $8 million, respectively, of settlement charges for pension plans.
The company’s GAAP and adjusted tax rates in the third quarter of 2026 were impacted by a $161 million deferred tax benefit resulting from the
recognition of tax attributes related to a domestication transaction. The company’s GAAP tax rate in the third quarter of 2026 was also impacted
by a $171 million tax expense related to the tax gain associated with the sale of the microbiology business that was completed during the
quarter. The company’s GAAP and adjusted tax rates in the first nine months of 2026 were impacted by $175 million of deferred tax benefits
resulting from the recognition of tax attributes related to domestication transactions and a deferred tax benefit of $148 million in jurisdictions
where the deferred tax assets are now expected to be realized due to forecasted income. The company’s GAAP and adjusted tax rates in the
third quarter of 2025 were impacted by an $86 million tax benefit from tax return reassessments. The company’s GAAP tax rate in the third
quarter of 2025 was also impacted by tax legislation enacted during the quarter. The company’s GAAP and adjusted tax rates in the first nine
months of 2025 were impacted by a $125 million deferred tax benefit resulting from the recognition of a tax
35

-- 35 of 46 --

THERMO FISHER SCIENTIFIC INC.
attribute related to a domestication transaction, a deferred tax benefit of $153 million related to capital losses generated as part of intra-entity
transactions, and a $93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income
(Note 7).
The effective tax rates in both 2026 and 2025 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the
non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax
expense for financial reporting purposes and are expected to total approximately $1.5 billion in 2026.
The company expects its GAAP effective tax rate in 2026 will be between 9% and 11% based on currently forecasted rates of profitability in the
countries in which the company conducts business and generates foreign tax credits. The effective tax rate can vary significantly from period to
period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 11.5% in 2026.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax
rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in
countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax
provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially
affect the company’s income tax provision or net income.
Weighted average diluted shares decreased in 2026 compared to 2025, primarily due to share repurchases, net of option dilution.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its
capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
(In millions) 	September 26, 2026 	December 31, 2025
Cash and cash equivalents 	$ 	5,461 	$ 	9,852
Short-term investments 	600 	253
Total debt 	41,370 	39,384
Approximately half of the company’s cash balances and cash flows from operations are generated outside the U.S. The company uses its non-
U.S. cash for needs outside of the U.S., including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign
subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns
of capital, as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the
dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects
from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing
capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future,
including at least the next 24 months.
As of September 26, 2026, the company’s short-term obligations and current maturities of long-term obligations totaled $2.26 billion. The
company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 3). If
the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source
of funds in the event that commercial paper markets are not available. As of September 26, 2026, no borrowings were outstanding under the
company’s revolving credit facility.
36

-- 36 of 46 --

THERMO FISHER SCIENTIFIC INC.
Nine months ended
(In millions) 	September 26, 2026 	September 27, 2025
Net cash provided by operating activities 	$ 	5,867 	$ 	4,361
Net cash used in investing activities 	(8,874) 	(4,938)
Net cash used in financing activities 	(1,541) 	(1,725)
Free cash flow (non-GAAP measure) 	4,618 	3,319
Operating Activities
During the first nine months of 2026, cash provided by net income was offset in part by investments in working capital. An increase in accounts
receivable used cash of $0.54 billion. A decrease in accounts payable used cash of $0.43 billion. Cash payments for income taxes were $0.94
billion during the first nine months of 2026.
During the first nine months of 2025, cash provided by income was offset in part by investments in working capital. Changes in other assets and
liabilities used cash of $1.21 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes
were $1.60 billion during the first nine months of 2025.
Investing Activities
During the first nine months of 2026, acquisitions used cash of $8.88 billion, and proceeds from the sale of the company’s microbiology business
provided cash of $1.02 billion (Note 12). Purchases of property, plant and equipment for capacity and capability investments used cash of $1.26
billion.
During the first nine months of 2025, acquisitions used cash of $4.04 billion. The company’s investing activities also included $1.06 billion for the
purchase of property, plant and equipment for capacity and capability investments.
The company expects that for all of 2026, expenditures for property, plant and equipment, net of disposals, will be between $1.9 billion and $2.0
billion.
Financing Activities
During the first nine months of 2026, issuance of debt provided $5.24 billion of cash. Repayment of debt used cash of $2.52 billion. The
company’s financing activities also included the repurchase of $4.00 billion of the company’s common stock (6.9 million shares), and the
payment of $0.51 billion in cash dividends. On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion of the
company’s common stock. All of the shares of common stock repurchased by the company during the first nine months of 2026 were under this
program. At October 30, 2026, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
During the first nine months of 2025, issuance of debt and net commercial paper activity provided $3.34 billion of cash. Repayment of debt used
cash of $1.63 billion. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.8 million
shares), of which $0.04 billion settled in the fourth quarter of 2025, and the payment of $0.47 billion in cash dividends.
The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, did
not change materially subsequent to December 31, 2025, except in connection with the completion of the Clario acquisition, which occurred on
March 24, 2026 (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with GAAP, we use certain non-GAAP financial measures such as organic revenue
growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency
translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-
term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on
revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as
well as to compare revenues of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS.
We believe that the use of these non-GAAP financial measures, in addition to
37

-- 37 of 46 --

THERMO FISHER SCIENTIFIC INC.
GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how
management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods,
forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-
making and for compensation purposes. To calculate these measures we exclude, as applicable:
• Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-
related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining
short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are
indicative of our normal operating costs.
• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and
consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale
abandonment of product lines are not indicative of our normal operating costs.
• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either
isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses,
product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of
debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast
accurately for future periods.
• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price
for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows
comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both
acquisitive and non-acquisitive peer companies.
• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in
deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations
and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to
generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the
strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-
discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be
considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-
GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Consolidated Results” and
“Segment Results” sections and below.
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(Dollars in millions except per share amounts) 	2026 	2025 	2026 	2025
Reconciliation of adjusted operating income
GAAP operating income 	$ 	2,263 $ 	1,941 $ 	6,213 $ 	5,491
Cost of revenues adjustments (a) 	9 	10 	51 	31
Selling, general and administrative expenses adjustments (b) 	(20) 	66 	59 	99
Restructuring and other costs (c) 	199 	135 	346 	316
Amortization of acquisition-related intangible assets 	519 	435 	1,433 	1,294
Adjusted operating income (non-GAAP measure) 	$ 	2,968 $ 	2,587 $ 	8,102 $ 	7,231
38

-- 38 of 46 --

THERMO FISHER SCIENTIFIC INC.
Three months ended 	Nine months ended
September 26, 	September 27, 	September 26, 	September 27,
(Dollars in millions except per share amounts) 	2026 	2025 	2026 	2025
Reconciliation of adjusted operating income margin
GAAP operating income margin 	18.6 % 	17.4 % 	17.7 % 	17.0 %
Cost of revenues adjustments (a) 	0.1 % 	0.1 % 	0.1 % 	0.1 %
Selling, general and administrative expenses adjustments (b) 	(0.2)% 	0.6 % 	0.2 % 	0.3 %
Restructuring and other costs (c) 	1.6 % 	1.2 % 	1.0 % 	1.0 %
Amortization of acquisition-related intangible assets 	4.3 % 	3.9 % 	4.1 % 	4.0 %
Adjusted operating income margin (non-GAAP measure) 	24.5 % 	23.3 % 	23.1 % 	22.4 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) 	$ 	(10) 	$ 	(2) 	$ 	13 	$ 	(18)
Adjustments (d) 	14 	(5) 	(15) 	(1)
Adjusted other income/(expense) (non-GAAP measure) 	$ 	5 	$ 	(7) 	$ 	(3) 	$ 	(19)
Reconciliation of adjusted tax rate
GAAP tax rate 	16.9 % 	11.3 % 	10.3 % 	7.6 %
Adjustments (e) 	(5.3)% 	(0.3)% 	1.0 % 	2.7 %
Adjusted tax rate (non-GAAP measure) 	11.6 % 	11.0 % 	11.3 % 	10.4 %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo
Fisher Scientific Inc. 	$ 	4.64 	$ 	4.27 	$ 	13.75 	$ 	12.53
Cost of revenues adjustments (a) 	0.02 	0.03 	0.14 	0.08
Selling, general and administrative expenses adjustments (b) 	(0.06) 	0.17 	0.16 	0.26
Restructuring and other costs (c) 	0.54 	0.36 	0.93 	0.83
Amortization of acquisition-related intangible assets 	1.40 	1.15 	3.86 	3.42
Other income/expense adjustments (d) 	0.04 	(0.01) 	(0.04) 	0.00
Income taxes adjustments (e) 	0.07 	(0.17) 	(0.72) 	(0.85)
Equity in earnings/losses of unconsolidated entities 	0.02 	(0.01) 	0.09 	0.02
Noncontrolling interests adjustments (f) 	— 	0.00 	— 	0.00
Adjusted EPS (non-GAAP measure) 	$ 	6.68 	$ 	5.79 	$ 	18.15 	$ 	16.30
Reconciliation of free cash flow
GAAP net cash provided by operating activities 	$ 	2,551 	$ 	2,239 	$ 	5,867 	$ 	4,361
Purchases of property, plant and equipment 	(437) 	(404) 	(1,263) 	(1,060)
Proceeds from sale of property, plant and equipment 	1 	5 	14 	17
Free cash flow (non-GAAP measure) 	$ 	2,115 	$ 	1,840 	$ 	4,618 	$ 	3,319
(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale
of inventory revalued at the date of acquisition. Adjusted results in 2026 also exclude $16 million of transaction-related costs.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent
acquisition consideration, accelerated depreciation on fixed assets to be abandoned due to facility consolidations, and charges for product liability litigation.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-
acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and
real estate consolidations. Adjusted results in 2026 exclude $72 million of gain on the sale of a business and $244 million for a held-for-sale loss. Adjusted
results in 2025 also exclude $51 million of charges for disposition of a consolidated joint venture.
39

-- 39 of 46 --

THERMO FISHER SCIENTIFIC INC.
(d) Adjusted results exclude net gains/losses on investments and settlement charges for pension plans. Adjusted results in 2026 also exclude $6 million of
business interruption recoveries.
(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of
tax rate/law changes, and the tax impacts from audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for
2025 describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been
no significant changes in the company’s critical accounting policies during the first nine months of 2026.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its
exposure discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the
effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the
Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment
in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer
and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the
reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) during the fiscal quarter ended September 26, 2026, that have materially affected or are reasonably likely to materially affect the
company’s internal control over financial reporting.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues.
See Note 5 to our Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”
Item 1A. Risk Factors
The risks that we believe are material to our investors are detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-
K for the year ended December 31, 2025 (which is on file with the SEC).
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
There was no share repurchase activity for the company's third quarter of 2026. On November 6, 2025, the Board of Directors authorized the
repurchase of up to $5.00 billion of the company’s common stock. At September 26, 2026, $1.00 billion was available for future repurchases of
the company’s common stock under this authorization.
40

-- 40 of 46 --

THERMO FISHER SCIENTIFIC INC.
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended September 26, 2026, no director or executive officer of the company adopted, modified or terminated a “Rule
10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Item 6. Exhibits
Exhibit
Number 	Description of Exhibit
31.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
31.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
32.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.**
32.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.**
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
the Inline XBRL document.
101.SCH 	XBRL Taxonomy Extension Schema Document.
101.CAL 	XBRL Taxonomy Calculation Linkbase Document.
101.DEF 	XBRL Taxonomy Definition Linkbase Document.
101.LAB 	XBRL Taxonomy Label Linkbase Document.
101.PRE 	XBRL Taxonomy Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each
instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.
_______________________
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not
deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically
incorporates it by reference.
41

-- 41 of 46 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: October 30, 2026 	THERMO FISHER SCIENTIFIC INC.
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer
/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer
42

-- 42 of 46 --

Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
Date: October 30, 2026
/s/ Marc N. Casper
Marc N. Casper
Chairman and Chief Executive Officer

-- 43 of 46 --

Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, James R. Meyer, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
Date: October 30, 2026
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer

-- 44 of 46 --

Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended September 26,
2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman and
Chief Executive Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Dated: October 30, 2026
/s/ Marc N. Casper
Marc N. Casper
Chairman and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and
will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 45 of 46 --

Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended September 26,
2026 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James R. Meyer, Senior Vice
President and Chief Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-
14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Dated: October 30, 2026
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and
will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 46 of 46 --